Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
1. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising:
a) assessing the renal function of the patient; and
b) administering empagliflozin to the patient if the eGFR of the patient is
≥45 ml/min/1.73 m 2 and <60 ml/min/1.73 m 2 ,
wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg, and
wherein the glycemic control in said patient is improved.
2. The method according to claim 1 , wherein empagliflozin is administered in a total daily amount of 10 mg.
3. The method according to claim 1 , wherein empagliflozin is administered in a total daily amount of 25 mg.
4. The method according to claim 1 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 10 mg of empagliflozin.
5. The method according to claim 1 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 25 mg of empagliflozin.
6. The method according to claim 1 , further comprising administering metformin to the patient.
7. A method of treating type 2 diabetes mellitus comprising:
a) assessing the renal function of a patient with type 2 diabetes mellitus; and
b) administering empagliflozin to the patient if the eGFR of the patient is
≥45 ml/min/1.73 m 2 and <60 ml/min/1.73 m 2 ,
wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg, and
wherein the glycemic control in said patient is improved.
8. The method according to claim 7 , wherein empagliflozin is administered in a total daily amount of 10 mg.
9. The method according to claim 7 , wherein empagliflozin is administered in a total daily amount of 25 mg.
10. The method according to claim 7 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 10 mg of empagliflozin.
11. The method according to claim 7 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 25 mg of empagliflozin.
12. The method according to claim 7 , further comprising administering metformin to the patient.
13. A method for improving glycemic control in a patient with type 2 diabetes mellitus comprising:
a) assessing the renal function of the patient; and
b) administering empagliflozin to the patient if the eGFR of the patient is
≥30 ml/min/1.73 m2 and <60 ml/min/1.73 m2,
wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg, and
wherein the glycemic control in said patient is improved.
14. The method according to claim 13 , wherein empagliflozin is administered in a total daily amount of 10 mg.
15. The method according to claim 13 , wherein empagliflozin is administered in a total daily amount of 25 mg.
16. The method according to claim 13 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 10 mg of empagliflozin.
17. The method according to claim 13 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 25 mg of empagliflozin.
18. The method according to claim 13 , further comprising administering metformin to the patient.
19. A method of treating type 2 diabetes mellitus comprising:
a) assessing the renal function of a patient with type 2 diabetes mellitus; and
b) administering empagliflozin to the patient if the eGFR of the patient is
≥30 ml/min/1.73 m 2 and <60 ml/min/1.73 m 2 ,
wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg, and
wherein the glycemic control in said patient is improved.
20. The method according to claim 19 , wherein empagliflozin is administered in a total daily amount of 10 mg.
21. The method according to claim 19 , wherein empagliflozin is administered in a total daily amount of 25 mg.
22. The method according to claim 19 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 10 mg of empagliflozin.
23. The method according to claim 19 , wherein empagliflozin is administered orally once daily as a pharmaceutical composition comprising 25 mg of empagliflozin.
24. The method according to claim 19 , further comprising administering metformin to the patient.